Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

SARS-CoV-2 Vaccine Candidates In or Nearing Clinical Trials

Posted on May 6th, 2020 by

COVID-19

The number of vaccines in the pipeline to battle the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has reached to >70 candidates [1,2]. Many different vaccination strategies are being tested, even a noncoronavirus-specific candidate (Bacille Calmette-Guerin vaccine) [2,3] is being investigated because of its potential to promote a less inflammatory immune response to respiratory pathogens [2]. However, a SARS-Cov-2–specific vaccine will likely be a better strategy.

(more…)

Infographic: Elsevier’s Professional Services team provides COVID-19 insights

Posted on May 1st, 2020 by

COVID-19

Check out a special infographic we created to show how Elsevier’s Professional Services team can support your COVID-19 research.

(more…)

Nucleic Acid–Based Vaccines in Development for SARS-CoV-2

Posted on May 1st, 2020 by

COVID-19

With the coronavirus disease 2019 (COVID-19) case and death count climbing [1] despite multiple industry shutdowns and extensive social distancing efforts, it has become clear that a vaccine is required to control the spread of the COVID-19 causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many different researchers, institutes and companies specializing in vaccine development across the world have entered the race and announced a candidate, resulting in an astonishingly large number (>70) of vaccines in the pipeline [2,3].

(more…)

Mathematical modeling the emergence and spread of new pathogens: Insight for SARS-CoV-2 and other similar viruses

Posted on April 24th, 2020 by

COVID-19

Knowing if and how rapidly an emerging pathogen will spread through a population enables public health officials to make well-informed decisions to protect the public. Mathematical modeling can provide them this means to predict pathogen spread, but modeling previously unheard of pathogens, like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is challenging.

(more…)

PharmaPendium and ExactCure review 20 approved drugs for COVID-19 therapies

Posted on April 21st, 2020 by

COVID-19

Currently there is no miracle drug out there to cure COVID-19 [1]. Drugs such as the anti-malarial hydroxychloroquine have shown to be helpful based on “anecdotal evidence” [2]. However, scientists are still debating its efficacy, and some have warned of the dangers of authorizing the use of such drugs too quickly in the absence of wider studies. The side effects can be severe – especially in the case of overdose. Much more research is needed, but time is short, and the use of model simulations based on patient specifics and for diverse candidate drugs could be a game changer.

(more…)

Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development

Posted on April 17th, 2020 by

COVID-19

Coronavirus disease 19 (COVID-19) is now present in 230 countries, areas or territories around the world. As of April 15, 2020, the World Health Organization has reported 117,021 deaths [1]. Researchers across the globe are collaborating to develop antivirals and vaccines. In this context, understanding the vast amount of data published on SARS-CoV and other viruses is key to tackling the challenge of containing the 2019 novel coronavirus (SARS-CoV-2).

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. …
  8. 77


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.